-
Mashup Score: 1Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer - Nature Genetics - 1 year(s) ago
Genomic and transcriptomic analysis of 393 non-small cell lung cancer patients treated with checkpoint inhibitors identifies molecular features associated with response.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Course DirectorsJustin Gainor, MDDirector, Center for Thoracic Cancers,Director of Targeted Immunotherapy,Massachusetts General Hospital Cancer Center;Associate Professor of Medicine, Harvard Medical SchoolKrista Rubin, MS, FNP-BCNurse Practitioner, Center for Melanoma,Massachusetts General Hospital Cancer Center Ryan Sullivan, MDPhysician Investigator, Cancer Center, Mass General Research…
Source: cpd.partners.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Countdown to "Advances in Cancer Immunotherapy: Annual Update." Less than one month away (May 1-2 at the Westin Copley Place in Boston). Register now! @MGHCancerCenter @MGHMedicine https://t.co/J6poppFKI2 https://t.co/G9E0Q94Gxs
-
-
Mashup Score: 0
Course DirectorsJustin Gainor, MDDirector, Center for Thoracic Cancers,Director of Targeted Immunotherapy,Massachusetts General Hospital Cancer Center;Associate Professor of Medicine, Harvard Medical SchoolKrista Rubin, MS, FNP-BCNurse Practitioner, Center for Melanoma,Massachusetts General Hospital Cancer Center Ryan Sullivan, MDPhysician Investigator, Cancer Center, Mass General Research…
Source: cpd.partners.orgCategories: Latest Headlines, Oncologists1Tweet-
Join us on May 1st-2nd for our Annual Update in Cancer Immunotherapy! Virtual and in-person options available! Expert faculty spanning basic, translational and clinical investigation. @MGHCancerCenter https://t.co/hdWX3ejly0 https://t.co/TGFu0u0G0Q
-
-
Mashup Score: 2Join our Cloud HD Video Meeting - 1 year(s) ago
Zoom is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile, desktop, and room systems. Zoom Rooms is the original software-based conference room solution used around the world in board, conference, huddle, and training rooms, as well as executive offices and classrooms. Founded in 2011,…
Source: Zoom VideoCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @lcrf_org: Join LCRF 2022 grantee, Dr. Jamie Schneider, Sunday evening, March at 7 pm ET for ALKtALK. Go to https://t.co/KSfucrTrRv to j…
-
-
Mashup Score: 6Poems, Joan Mitchell; Author: Nathan Kernan; Publisher: Tyler Graphics, Ltd., Mount Kisco, New York ^ Minneapolis Institute of Art - 1 year(s) ago
Near the end of her life, Joan Mitchell was asked by legendary print publisher Ken Tyler to collaborate on a book project with the American poet and writer Nathan Kernan (born 1950). Enthusiastic about the idea, Mitchell responded with a series of eight brilliantly colored abstract illuminations. Her boldly gestural images are not literal illustrations of Kernan’s poems, but instead complement…
Source: collections.artsmia.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ArtistJMitchell: Joan Mitchell, Poems, 1992 #minneapolisinstituteofart #joanmitchell https://t.co/y9qXqwgCx1 https://t.co/SVWv0SVljD
-
-
Mashup Score: 1Clinical Updates From San Antonio #1 - 1 year(s) ago
On Tuesday, December 13, 2022 at 6:00 PM EST, Drs. Rahul Gosain, Rohit Gosain, and Sara Tolaney will give updates in breast cancer from the conference in San Antonio. They will discuss the use of CDK4/6 inhibitors in HR+/HER2- breast cancer.Join us on Twitter: https://Twitter.com/SoMeCME
Source: www.addevent.comCategories: Latest Headlines, Oncologists1Tweet-
RT @SoMeCME: 📣 Upcoming live activities on @SoMeCME! ⭐ #SABCSUpdate #1 : https://t.co/wmGZiduM1Q 🩺 #NSCLCBrief #2 : https://t.co/TfH5v75VP…
-
-
Mashup Score: 1Long-term Outcomes and Emerging Combinations With Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A GameOn! Challenge - 2 year(s) ago
Education Lab | Treatment of advanced non-small cell lung cancer (NSCLC) has rapidly evolved with the availability of immune checkpoint inhibitor (ICI) therapy. The integration of immunotherapy into treatment protocols offers the potential for durable treatment responses and improved survival for patients with tumors that lack targetable molecular alterations. As increased long-term data become…
Source: cme.healio.comCategories: Latest Headlines, Oncologists1Tweet-
RT @Oncology_CE: 🚨NEW GameOn! Challenge with @JustinGainor & @RachelSanbornMD is now available! >> https://t.co/AInzDLc0CN https://t.co/jLM…
-
-
Mashup Score: 3LUNGSTONG | 5k Run - 2 year(s) ago
Each year hundreds of runners and walkers come out in support of lung cancer research at this family-friendly event. 100% of race proceeds benefit Massachusetts General Cancer Center.
Source: LUNGSTRONG 2018Categories: Latest Headlines, Oncologists1Tweet-
Just registered for the 2022 LUNGSTRONG 5K Run/1.5K Walk. Join me and the rest of @MGHThoracicOnc for a great event on May 15th to support lung cancer research. @LUNGSTRONGorg https://t.co/12qeboQWQB https://t.co/KfVduMTAbi
-
-
Mashup Score: 3Advances in Cancer Immunotherapy: Annual Update - 2 year(s) ago
Cancer treatment has evolved significantly over the past decade from a treatment paradigm anchored on surgery, chemotherapy, and radiotherapy, to one embracing molecularly-targeted therapies disrupting tumor-specific signaling pathways, as well as new approaches to mobilize the immune system. For clinicians trying to keep current with advancing immuno-oncology principles and research, the pace of…
Source: cmeregistration.hms.harvard.eduCategories: Latest Headlines, Oncologists1Tweet-
Only 1 month away! Please join me and fellow course directors Ryan Sullivan and Krista Rubin for our Annual Update on Cancer Immunotherapy. Great faculty and discussions, including virtual tumor boards on IO tox and neoadjuvant/adjuvant IO. https://t.co/qv2LeAhzrd https://t.co/eCss2IzCgA
-
-
Mashup Score: 3Advances in Cancer Immunotherapy: Annual Update - 2 year(s) ago
Cancer treatment has evolved significantly over the past decade from a treatment paradigm anchored on surgery, chemotherapy, and radiotherapy, to one embracing molecularly-targeted therapies disrupting tumor-specific signaling pathways, as well as new approaches to mobilize the immune system. For clinicians trying to keep current with advancing immuno-oncology principles and research, the pace of…
Source: cmeregistration.hms.harvard.eduCategories: Hem/Oncs, Latest HeadlinesTweet-
Save the date for our virtual CME "Advances in Cancer Immunotherapy: Annual Update" May 5-6, 2022. Timely discussions by world-class faculty. Early registration ends this Friday! @MGHCancerCenter @harvardmed https://t.co/5cbl7HeZzw
-
(1/3) Excited to share our work on genomic and transcriptomic predictors of response to PD-(L)1 inhibitors in NSCLC @NatureGenet; nearly 400 pts and growing, forming the SU2C/Mark Foundation cohort https://t.co/NwCYZv71ik https://t.co/B43PFdiF6o